Secondary Pulmonary Alveolar Proteinosis Development during the Treatment for Anti-aminoacyl-tRNA Synthetase Antibody-positive Interstitial Lung Disease
A 70-year-old woman with anti-aminoacyl-tRNA synthetase (ARS) antibody-positive interstitial lung disease (ARS-ILD) received daily medications and regular cyclophosphamide cycles for recurring exacerbations. Approximately four years after immunosuppression initiation, the patient was admitted for progressive dyspnea on exertion. Chest computed tomography (CT) findings were suggestive of acute exacerbation. Despite intensified immunosuppressive treatment, the radiographic findings worsened, and serum Krebs von den Lungen-6 (KL-6) levels increased. A bronchoalveolar lavage fluid (BALF) examination revealed amorphous globules and alveolar macrophages with eosinophilic granules. Owing to negative anti-GM-CSF antibody tests, a diagnosis of secondary pulmonary alveolar proteinosis (PAP) was established.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Internal medicine (Tokyo, Japan) - (2024) vom: 25. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Matsuoka, Suzuka [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-aminoacyl-tRNA synthetase antibody-positive interstitial lung disease |
|---|
| Anmerkungen: |
Date Revised 24.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2169/internalmedicine.3327-23 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370124731 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370124731 | ||
| 003 | DE-627 | ||
| 005 | 20240325235750.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240325s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2169/internalmedicine.3327-23 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1347.xml |
| 035 | |a (DE-627)NLM370124731 | ||
| 035 | |a (NLM)38522908 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Matsuoka, Suzuka |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Secondary Pulmonary Alveolar Proteinosis Development during the Treatment for Anti-aminoacyl-tRNA Synthetase Antibody-positive Interstitial Lung Disease |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a A 70-year-old woman with anti-aminoacyl-tRNA synthetase (ARS) antibody-positive interstitial lung disease (ARS-ILD) received daily medications and regular cyclophosphamide cycles for recurring exacerbations. Approximately four years after immunosuppression initiation, the patient was admitted for progressive dyspnea on exertion. Chest computed tomography (CT) findings were suggestive of acute exacerbation. Despite intensified immunosuppressive treatment, the radiographic findings worsened, and serum Krebs von den Lungen-6 (KL-6) levels increased. A bronchoalveolar lavage fluid (BALF) examination revealed amorphous globules and alveolar macrophages with eosinophilic granules. Owing to negative anti-GM-CSF antibody tests, a diagnosis of secondary pulmonary alveolar proteinosis (PAP) was established | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a anti-aminoacyl-tRNA synthetase antibody-positive interstitial lung disease | |
| 650 | 4 | |a immunosuppressants | |
| 650 | 4 | |a secondary pulmonary alveolar proteinosis | |
| 650 | 4 | |a steroid | |
| 700 | 1 | |a Fujiwara, Keiichi |e verfasserin |4 aut | |
| 700 | 1 | |a Takigawa, Yuki |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Saki |e verfasserin |4 aut | |
| 700 | 1 | |a Mitsumune, Sho |e verfasserin |4 aut | |
| 700 | 1 | |a Shiraha, Keisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Goda, Mayu |e verfasserin |4 aut | |
| 700 | 1 | |a Inoue, Tomoyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Fujiwara, Miho |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamura, Eri |e verfasserin |4 aut | |
| 700 | 1 | |a Watanabe, Hiromi |e verfasserin |4 aut | |
| 700 | 1 | |a Kudo, Kenichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Akiko |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Shibayama, Takuo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Internal medicine (Tokyo, Japan) |d 1996 |g (2024) vom: 25. März |w (DE-627)NLM012606731 |x 1349-7235 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:25 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2169/internalmedicine.3327-23 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 25 |c 03 | ||